oxysterol binding protein like 10Genealiases: ORP10 · OSBP9
Q-omics provides the consensus-scored OSBPL10 profile across patient tissues and cancer cell-line models. OSBPL10 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OSBPL10 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, OSBPL10 RNA expression shows 20,226 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where OSBPL10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OSBPL10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OSBPL10 survival associations across molecular data types. OSBPL10 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OSBPL10 RNA expression–survival associations across cancer types. High OSBPL10 expression shows unfavorable associations in MESO, BLCA, LGG and ACC, but favorable associations in KIRC and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OSBPL10 RNA expression.
This table summarizes OSBPL10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OSBPL10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OSBPL10 shows lower tumor expression in KICH and BLCA and higher tumor expression in COAD, THCA, HNSC and STAD. The COAD box plot shows higher OSBPL10 RNA expression in tumor versus normal tissue (log2 FC = +0.907, t-test p < 0.001).
This table shows molecular features associated with OSBPL10 in patient tissues and cancer cell lines. In patient samples, OSBPL10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OSBPL10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
